Previous 10 | Next 10 |
The first and only Water Gradient contact lens for patients with astigmatism, available in the U.S. beginning in March DAILIES TOTAL1 for Astigmatism joins DAILIES TOTAL1 sphere and multifocal for a full portfolio designed for the premium, daily disposable lens market ...
Alcon will leverage its global footprint and leadership in ophthalmology to drive future growth, bringing this innovative device to more patients worldwide Ivantis associates, including manufacturing and sales, are immediately integrated into Alcon to ensure continuity for n...
Wedgewood Partners’ 13F portfolio value increased ~3% from ~$690M to ~$709M this quarter. They added UnitedHealth and increased Taiwan Semi while reducing Starbucks, Keysight Technologies, and Alphabet. Their top five positions are at 37% of the overall portfolio. For...
Alcon has built a leading position over time in the surgical and vision care markets. This is a high-quality business with predictive cash flows fitting the value framework. On the back of strong results, I have raised ALC's fair value from roughly $61.00 per share to approximately $7...
PRECISION1 is the first mainstream daily disposable contact lens to use SMARTSURFACE Technology to deliver lasting visual performance and comfort 1 Available in Europe, PRECISION1 for Astigmatism features the proven PRECISION BALANCE 8|4 lens design for a stable contact lens-w...
The following slide deck was published by Alcon Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Alcon Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Alcon inc (NYSE: ALC) Q3 2021 Earnings Call Nov 10, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Alcon inc (ALC) Q3 2021 Earnings Call Transcript
Alcon Inc. (ALC) Q3 2021 Results Conference Call November 10, 2021 8:00 AM ET Company Participants David Endicott – Chief Executive Officer Tim Stonesifer – Chief Financial Officer Karen King – Senior Vice President, Head of Global Corporate Affairs and IR Conference Call...
Alcon (NYSE:ALC) swung to net income of $2M in Q3 2021 from a loss of $147M in prior-year due in part to a boost in sales in its surgical business. Sales in that division were ~1.2B, a ~17% increase compared to Q3 2020. Vision care sales rose ~12% to $923M. R&D expenses increased 47% to 3...
Alcon (NYSE:ALC): Q3 Non-GAAP EPS of $0.54 beats by $0.03; GAAP EPS of $0.00 misses by $0.15. Revenue of $2.08B (+14.3% Y/Y) beats by $30M. Shares -2%. Press Release For further details see: Alcon EPS beats by $0.03, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...